After two rounds of review inquiries, Jun Cheng technology's restructuring failed, and the symbol company's financial irregularities have become the focus of regulatory attention. | Quick read announcement.

Jun Cheng Technology announced the abandonment of the planned assets restructuring that had been planned for over a year. This involved the acquisition of a controlling stake in the automotive instrument company New Times for 0.247 billion yuan; During the planning period, the company received two rounds of "Inquiry Letters for Review" issued by the Shenzhen Stock Exchange, and recently disclosed a revised report draft; The Shenzhen Stock Exchange has noticed that New Times has used borrowed funds for the family consumption of the actual controller, involving behaviors such as receiving, transferring, and misappropriating funds by others.

cls.cnDec 6 23:28

Shenzhen Transsion Holdings Co., Ltd.: Currently negotiating patents with rights holders. Emerging markets are still in the trend of "switching from feature phones to asia vets." | Direct coverage of the earnings conference.

① Zhu Zhaojiang stated that overall, the penetration rate of asia vets in emerging markets is lower compared to North America, Western Europe, and developed economies in the mature Asia-Pacific and china market. The transition from feature phones to asia vets remains an important factor driving the growth of the asia vets market in emerging markets; ② He mentioned that Transsion is currently in patent negotiations with patent holders to determine reasonable licensing fees under the framework of fair, reasonable, and non-discriminatory principles.

cls.cnDec 3 19:09

Increase the proportion of high value-added products henan mingtai al.industrial plans to change part of the raised funds investment projects|Speed ??reading announcement

1. Capitalizing on the opportunity of the "Zhengzhou-Kaifeng 3 million-vehicle automotive industry belt," Henan Mingtai Al.Industrial is increasing investments in new energy battery materials and aluminum sheet strips for autos; 2. The company has already entered high-tech, high value-added fields such as new energy, aluminum for new materials, aluminum for transportation, and aluminum for lightweight autos.

cls.cnNov 29 22:11

Private capital will be introduced into new approved projects. China National Nuclear Power is still in a stage of rapid development and growth | Directly hitting the earnings conference.

① The company will introduce private capital into the newly approved projects; ② "The company's asset scale has exceeded 600 billion yuan and is still in a rapid development and growth phase."

cls.cnNov 27 22:44

Tasly Pharmaceutical Group: Some products price reduction led to a decline in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Focus on earnings conference

① Affected by the overall low prosperity of the pharmacy industry, the company's pharmaceutical commerce sector saw a decline in revenue in the third quarter this year; the pharmaceutical industry sector's revenue grew year-on-year, but price reductions on some products led to a decrease in gross margin, and the company expects the gross margin to remain stable in the future. ② Regarding the equity trade matters between the company's major shareholder and china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting various works for this transaction.

cls.cnNov 27 22:29

Clinical results did not meet expectations, tasly pharmaceutical group suspends the eight-year development "marathon" of the new cancer drug | Quick read announcement.

① Tasly Pharmaceutical Group announced the suspension of research and development for its Anmeimuk monoclonal antibody, which has reached the phase IIb clinical research stage since its approval in 2016; ② According to clinical research results, the efficacy of Anmeimuk did not meet expectations, and competition with other EGFR monoclonal antibody biosimilars is intense; ③ This project also involves Sirun Pharmaceutical's shareholding, with Tasly Pharmaceutical Group and Sirun Pharmaceutical recording asset impairment losses of 0.162 billion yuan and 14.1448 million yuan, respectively.

cls.cnNov 23 00:06